Scientific article
Case report

Does telaprevir possess a direct antidiabetic effect?

Published inLiver international, vol. 34, no. 6, p. 967-969
Publication date2014

Hepatitis C virus (HCV) induces insulin resistance, which improves upon viral clearance. Telaprevir is a protease inhibitor effective against HCV genotype 1. We reported a case, whose history suggests that telaprevir may induce some antidiabetic effect independently of its suppression of HCV. A 56-year-old woman with obesity, type 2 diabetes treated with sitagliptin and metformin, and HCV-related cirrhosis was given triple therapy with pegylated interferon-alpha, ribavirin and telaprevir. After 2 weeks of treatment, HCV RNA was no longer detectable but the patient described a pronounced drop in the capillary glucose levels and episodes of hypoglycaemia that compelled her to stop all antidiabetic treatment. One month after stopping telaprevir, she had to resume her antidiabetic treatment, despite a persisting virological response. Despite reaching a sustained virological response, her diabetes progressed. Although the suppression of HCV replication may have played a role in reducing glucose intolerance, the fact that this patient resumed her prior antidiabetic treatment upon completing the telaprevir treatment, while still aviremic, suggests that telaprevir may have an additional antidiabetic effect. Further evidence about the possible role and mechanisms of telaprevir as antidiabetic agent is warranted.

Citation (ISO format)
TALLON DE LARA, Paulino et al. Does telaprevir possess a direct antidiabetic effect? In: Liver international, 2014, vol. 34, n° 6, p. 967–969. doi: 10.1111/liv.12440
Main files (1)
Article (Accepted version)
ISSN of the journal1478-3223

Technical informations

Creation10/27/2014 12:26:00 PM
First validation10/27/2014 12:26:00 PM
Update time03/14/2023 10:22:50 PM
Status update03/14/2023 10:22:49 PM
Last indexation08/29/2023 1:26:44 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack